The role of MITF as a mechanism of resistance to BRAF inhibition; however, was contradicted by findings, that show lower levels of MITF expression upon inhibition of MAPK signaling in melanoma, and a recent report, which predicts early resistance to ERK inhibitors in melanoma samples with low MITF and AXL receptor tyrosine kinase (AXL) ratios [73,74]. This evidence concerns the gene AXL and melanoma.